News | May 15, 2007

Boston Scientific’s OLYMPIA Trial Registers 23,000

May 16, 2007 — Boston Scientific Corp. has announced that it has completed enrollment in the European and Intercontinental phases (II and III) of its TAXUS OLYMPIA registry, bringing the total number of current patients to more than 23,000.

The registry is designed to evaluate the safety and performance of the Company's second-generation drug-eluting coronary stent (DES), TAXUS Liberte, in a real-world setting. OLYMPIA is the world's largest DES registry and plans to enroll at least 27,000 patients treated for complex coronary lesions at more than 400 centers worldwide.

"The size of the OLYMPIA registry is truly unprecedented in the DES field and will yield invaluable real-world information to the benefit of interventional cardiologists and those patients who suffer from cardiovascular disease," said Martyn Thomas, M.D., F.R.C.P., director of Invasive Cardiology, Kings College Hospital, London, and one of the coordinating investigators of the registry. "We expect the results from this registry to remain consistent with the safety and efficacy results we've seen in previous clinical trials featuring the TAXUS stent system in complex patients with complex lesions."

The multi-center, prospective, observational OLYMPIA registry will evaluate a variety of safety and performance measures, including the rate of repeat procedures (target lesion revascularization, or TLR) and major adverse cardiac events. Additionally, sub-analyses on complex patient groups such as diabetics, patients with multi-vessel disease, in-stent restenosis (re-blockages) or a prior history of heart attack will be performed.

For more information visit www.bostonscientific.com.

Related Content

Resolute Onyx Drug-Eluting Stent Noninferior to Polymer-Free Drug-Coated Stent With One-Month DAPT
News | Stents Drug Eluting | September 30, 2019
The first randomized trial to compare a durable polymer drug- eluting stent to a polymer-free drug-coated stent in...
Biodegradable Polymer Stent Plus Shortened DAPT Safe and Effective in Unprotected Left Main CAD
News | Stents Drug Eluting | September 30, 2019
A biodegradable polymer everolimus-eluting stent (BP-EES) followed by four months of dual antiplatelet therapy (DAPT)...
Superiority of Orsiro Over Xience Demonstrated in STEMI Patients
News | Stents Drug Eluting | September 05, 2019
Biotronik's ultrathin Orsiro stent demonstrated superiority over Xience with respect to target lesion failure (TLF) at...
Resolute Onyx Stent With Improved Radiographic Visibility Found to Be Safe and Effective
News | Stents Drug Eluting | October 01, 2018
October 1, 2018 — Recent results from the BIONYX randomized clinical study showed the novel, thin-strutted, polymer-c
Boston Scientific Receives FDA Approval for Eluvia Drug-Eluting Vascular Stent
Technology | Stents Drug Eluting | October 01, 2018
Boston Scientific announced that the U.S. Food and Drug Administration (FDA) has approved its Premarket Approval (PMA)...
Eluvia Drug-Eluting Stent Demonstrates Superior Patency in IMPERIAL Trial
News | Stents Drug Eluting | September 26, 2018
Positive 12-month data from the late-breaking IMPERIAL trial was presented at the 2018 Transcatheter Cardiovascular...
Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

News | Stents Drug Eluting | May 31, 2018
Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-...
Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial
News | Stents Drug Eluting | May 31, 2018
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials...
OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES
News | Stents Drug Eluting | May 29, 2018
Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early...